FHC
DNTH icon

First Horizon Corporation’s Dianthus Therapeutics DNTH Stock Holding History

First Horizon Corporation’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Buy
409
+26
+7% +$2.27K ﹤0.01% 760
2026
Q1 		$32.1K Buy
+383
New +$22.2K ﹤0.01% 763

Other funds holding DNTH

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

First Horizon Corporation's DNTH Position: Q2 2026 in Review

First Horizon Corporation increased its Dianthus Therapeutics (DNTH) stake by 6.8% in Q2 2026, buying an estimated $2.27K and bringing the position to 409 shares worth $39.9K. The position accounts for ﹤0.01% of the portfolio, ranked #760.

First Horizon Corporation first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 37 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • First Horizon Corporation held 409 shares of Dianthus Therapeutics worth $39.9K as of Q2 2026.
  • First Horizon Corporation bought 26 Dianthus Therapeutics shares in Q2 2026, an estimated $2.27K.
  • Dianthus Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #760 holding.
  • First Horizon Corporation first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 37 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.